Dr. Hamilton on Extended Adjuvant Therapy for HER2+ Breast Cancer

Erika P. Hamilton, MD
Published: Monday, Oct 16, 2017



Erika P. Hamilton, MD, director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute, discusses the role of extended adjuvant therapy for patients with HER2-positive breast cancer.

The role of extended adjuvant therapy in HER2-positive breast cancer may not be quite as clear as in estrogen receptor–positive disease, but there is a benefit, explains Hamilton. For those women who have a higher risk and are motivated, it is a reasonable option.

It is important to be careful with neratinib (Nerlynx) due to the toxicity, as there is significant diarrhea associated with the drug. For women who are having trouble tolerating it despite antidiarrheals, or for women who do not have a high risk for recurrence, it may not be worth it in this setting. However, for women who are high risk and can tolerate it, it is a valuable option, states Hamilton.
 


Erika P. Hamilton, MD, director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute, discusses the role of extended adjuvant therapy for patients with HER2-positive breast cancer.

The role of extended adjuvant therapy in HER2-positive breast cancer may not be quite as clear as in estrogen receptor–positive disease, but there is a benefit, explains Hamilton. For those women who have a higher risk and are motivated, it is a reasonable option.

It is important to be careful with neratinib (Nerlynx) due to the toxicity, as there is significant diarrhea associated with the drug. For women who are having trouble tolerating it despite antidiarrheals, or for women who do not have a high risk for recurrence, it may not be worth it in this setting. However, for women who are high risk and can tolerate it, it is a valuable option, states Hamilton.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x